Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Agilent Technologies, Inc. A

Healthcare — Diagnostics & Research
S&P 500 Member Dividend Champion (5y)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
3.17
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 3 1 — — — — 1 — — — 1
Insider Ownership
0.36%

Capital & Financial Ratios

Market Cap
44,080.00
Revenue
7,372.00
Net Income
1,440.00
Free Cash Flow
1,267.00
Net Debt
1,887.00
Current Ratio
2.05
Debt/Equity
0.50
P/E ratio
30.74
P/S ratio
5.99
P/B ratio
5.99
Past 5Y EPS Growth
5.63%
This Y EPS Growth
10.95%
Next Y EPS Growth
8.75%
Next 5Y EPS Growth
10.16%
in millions of $

Dividends

Payout Ratio
0.23
Annual Dividend Rate
0.90
Annual Dividend Yield
0.70%
total individual payouts
2028 ‡‡‡‡
2027 ‡‡‡
2026 1.03
—
—
—
2025 0.98
—
—
—
2024 0.96
—
—
—
—
2023 0.91
—
—
—
—
2022 1.07
—
—
—
—
—
2021 0.78
—
—
—
—
2020 0.54
—
—
—
2019 0.67
—
—
—
—
2018 0.61
—
—
—
—
2017 0.55
—
—
—
—
2016 0.48
—
—
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 1,590.00 1,329.00 1,789.00 1,758.00
Receivables 1,291.00 1,324.00 1,487.00 1,478.00
Inventory 1,031.00 972.00 1,025.00 1,117.00
Other 274.00 334.00 293.00 340.00
4,186.00 3,959.00 4,594.00 4,693.00
2023 2024 2025 Q'26
Payables 418.00 540.00 570.00 608.00
ST’ Debt 46.00 — — —
Other 1,066.00 — — —
1,603.00 1,895.00 2,347.00 2,289.00
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Jan Apr Jul Oct Year
’26 1,798.00 1,835.00 1,878.00 —
—
’25 1,681.00 1,668.00 1,738.00 1,861.00
6,948.00
’24 1,658.00 1,573.00 1,578.00 1,701.00
6,510.00
’23 1,756.00 1,717.00 1,672.00 1,688.00
6,833.00
’22 1,674.00 1,607.00 1,718.00 1,849.00
6,848.00
’21 1,548.00 1,525.00 1,586.00 1,660.00
6,319.00
’20 1,357.00 1,238.00 1,261.00 1,483.00
5,339.00
in millions of $

Operating Cash Flow

Jan Apr Jul Oct Year
’26 268.00 277.00 519.00 —
—
’25 431.00 221.00 362.00 545.00
1,559.00
’24 485.00 333.00 452.00 481.00
1,751.00
’23 296.00 398.00 562.00 516.00
1,772.00
’22 255.00 283.00 326.00 448.00
1,312.00
’21 238.00 472.00 334.00 441.00
1,485.00
’20 (59.00) 313.00 290.00 377.00
921.00
in millions of $

Free Cash Flow

Jan Apr Jul Oct Year
’26 175.00 201.00 439.00 —
—
’25 338.00 107.00 259.00 452.00
1,152.00
’24 395.00 230.00 360.00 388.00
1,373.00
’23 220.00 341.00 481.00 432.00
1,474.00
’22 180.00 219.00 244.00 378.00
1,021.00
’21 197.00 441.00 279.00 379.00
1,297.00
’20 (93.00) 280.00 266.00 350.00
803.00
in millions of $

EPS

Jan Apr Jul Oct Year
’26 1.07 1.20 1.28 —
—
’25 1.11 0.75 1.18 1.53
4.57
’24 1.18 1.05 0.97 1.22
4.43
’23 1.19 1.02 0.38 1.62
4.19
’22 0.93 0.91 1.10 1.23
4.18
’21 0.93 0.70 0.86 1.45
3.94
’20 0.63 0.32 0.64 0.71
2.30

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

1.8
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 112.52 96.80 124.16 96.43 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 160.26 159.59 155.35 160.27 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 18,100 18,100 17,900 18,100 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.38 0.38 0.36 0.38 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6,848.00 6,833.00 6,510.00 6,948.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 54.35% 50.71% 54.30% 52.43% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,504.00 1,339.00 1,521.00 1,435.00 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 21.96% 19.60% 23.36% 20.65% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,254.00 1,240.00 1,289.00 1,303.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 317.00 271.00 257.00 288.00 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 22.90 23.24 22.45 24.46 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 4.19 4.22 4.44 4.59 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.39 6.03 6.04 5.49 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.97) (1.01) (1.30) (1.43) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.41 5.01 4.73 4.06 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 17.74 19.88 20.34 23.74 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 299.00 294.00 290.00 284.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 32.94 24.50 29.35 31.96 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.04 4.45 5.80 5.98 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.80 5.20 6.41 6.17 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.30 4.62 6.12 6.17 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 42.37 21.47 29.09 37.15 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,312.00 1,772.00 1,751.00 1,559.00 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (291.00) (298.00) (378.00) (407.00) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,021.00 1,474.00 1,373.00 1,152.00 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,917.00 2,583.00 2,064.00 2,247.00 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,820.00 2,781.00 3,345.00 3,050.00 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,767.00 1,191.00 2,016.00 1,261.00 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5,305.00 5,845.00 5,898.00 6,741.00 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.81% 11.65% 11.40% 10.61% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.30% 11.99% 11.75% 11.55% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 23.45% 22.24% 21.95% 20.62% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Agilent Technologies (A), a powerhouse in life sciences, diagnostics, and chemical markets, trades at an undervalued level despite tripling from 2016 lows amid revenue growth from $4.2 billion to $6.51 billion in 2024 (6% CAGR). Post-pandemic dips reflect biopharma slowdowns and inventory destocking, but resilient efficiency—per-employee revenue steady at $364K-$384K—and strong margins (54% gross in 2024) highlight its operational strength. Analysts see a rebound, with revenue projected to hit $8.34 billion by 2028 and EPS surging over 50% to $6.80.

Profitability shines through EBT margins up to 23.4%, ROE above 20% (beating peers), and fortress balance sheet with book value per share doubling to $23.74. Free cash flow supports innovation capex and buybacks, while historical stock gains tightly track revenue peaks. Valuation metrics like 29x P/E and 5.8x P/S look attractive versus norms, implying 35% upside to mean targets.

Insider selling tempers short-term enthusiasm, but AI partnerships, gene therapy demand, and diagnostics recovery position Agilent for 20%+ annualized returns. Risks like China exposure and biopharma cuts exist, yet 54% margins provide a buffer—making this a compelling watch for growth-oriented investors. [Read the full analysis]

Read full commentary →

Agilent Technologies, Inc. (A) Latest News

News by impact score

Fine-tune

19 Sep

3 , 3:52 PM
Agilent Technologies promotes digital pathology adoption in labs with scanners processing 540 slides at once to drive workflow efficiency. Agilent targets pathology lab digitization to expand instrument sales in automation segment.

4 Sep

3 , 8:00 AM
Agilent Technologies launches the Agilent S540MD Slide Scanner System in the U.S. to expand its digital pathology offerings. U.S. launch of new slide scanner expands Agilent digital pathology portfolio and supports product innovation.

1 Sep

3 , 8:00 AM
Agilent Technologies introduces the Cary 635 FTIR Spectrometer. New spectrometer model supports product innovation in analytical instruments but remains incremental for overall trajectory.

31 Aug

3 transcript www.fool.com, 9:49 AM
Agilent Technologies held its Q3 2026 earnings call, covering quarterly financial results, business performance and forward outlook. Quarterly earnings calls typically provide financial metrics and guidance that can moderately influence near-term stock sentiment and analyst views.

3 , 9:15 AM
Agilent Technologies encounters varied growth prospects across international markets that influence its overall revenue streams and competitive stance. International market conditions moderately affect Agilent's financial results and positioning without triggering fundamental shifts.

28 Aug

3 , 10:50 PM
Agilent Technologies expanded its Non-GAAP margin by 320 basis points, with uncertainty over how much of the gain is repeatable. Non-GAAP margin expansion affects financial performance but limited long-term impact is likely without confirmed repeatability.

27 Aug

4 , 1:02 AM
Agilent Technologies reported strong core growth in its Q3 2026 earnings call and raised guidance. Strong core growth and raised guidance point to improved financial trajectory and market positioning for Agilent.

3 , 9:45 PM
Agilent Technologies posts strong Q2 results driven by product momentum, China recovery, and operating leverage gains. Q2 performance metrics point to improved financial results and operational efficiency.

3 , 7:12 PM
Agilent Technologies (A) latest update draws closer investor scrutiny. Update prompts investor attention with moderate potential effect on market performance.

3 , 6:13 PM
Agilent Technologies raised its 2026 outlook and posted margin gains, raising questions over required investor moves. Upgraded 2026 outlook and margin gains point to improved financial projections that may lift near-term sentiment.

3 transcript app.moby.co, 8:30 AM
Agilent Technologies, Inc. discussed its Q3 2026 financial results, operational performance, and forward outlook during the earnings call. Quarterly earnings results and guidance typically drive moderate short-term shifts in valuation and market sentiment.

3 investorshub.advfn.com, 6:11 AM
Agilent shares rise after strong Q3 results driven by improving demand, prompting an upgraded company guidance. Strong Q3 results and guidance upgrade signal improved demand and positive momentum for Agilent operations and outlook.

26 Aug

4 , 4:43 PM
Agilent Technologies beat estimates and raised guidance citing strong demand. Beating estimates with raised guidance signals stronger near-term financial results and lifts market valuation.

3 www.marketbeat.com, 7:04 PM
Agilent Technologies Q3 earnings call highlights revenue, EPS, segment performance across life sciences and diagnostics, plus raised full-year guidance amid steady demand. Q3 results and guidance updates supply financial metrics that can shift near-term investor views without altering long-term strategy.

3 , 6:00 PM
Agilent Technologies Inc. (A) reported Q3 earnings with key metrics compared to analyst estimates. Q3 earnings metrics versus estimates can shift near-term investor sentiment and valuation.

3 , 4:05 PM
Agilent Technologies reported third-quarter fiscal year 2026 financial results. Quarterly earnings release updates revenue and profit figures that can move near-term stock price but do not alter long-term company direction.

25 Aug

4 , 3:50 PM
Agilent Technologies, Inc. (A) will report Q2 earnings results tomorrow. Quarterly earnings releases frequently drive major stock moves and shift investor views on company trajectory.

21 Aug

4 247wallst.com, 10:00 AM
Agilent Technologies, Inc. (A) stock has a catalyst scheduled for August 26 that investors should monitor for potential effects on performance. August 26 catalyst holds potential to substantially shift Agilent stock trajectory and investor sentiment.

6 Aug

3 , 7:17 PM
Agilent Technologies (A) secured expanded EU approval for its ovarian cancer test. Expanded EU approval for one diagnostic test may lift Agilent's European sales in that segment but leaves overall operations and trajectory unchanged.

3 Aug

3 , 5:15 PM
Agilent Technologies expands its oncology diagnostics portfolio, prompting questions over whether growth can be sustained amid the move. Oncology diagnostics expansion may moderately affect competitive positioning without fundamentally shifting overall trajectory.

25 Jul

4 , 5:16 PM
Agilent Technologies received FDA approval for companion diagnostics tied to OPDIVO, prompting assessment of whether the stock remains undervalued. FDA approval for OPDIVO companion diagnostics strengthens Agilent's oncology diagnostics offerings and supports revenue growth.

3 , 11:12 AM
Agilent Technologies stock rose 5.4% after FDA approval of its OPDIVO cancer test. FDA clearance for OPDIVO test adds to Agilent's oncology diagnostics offerings.

23 Jul

3 , 8:00 AM
Agilent Technologies received EU approval for PD-L1 IHC 22C3 pharmDx in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. EU approval expands use of Agilent's pharmDx test into additional ovarian cancer indications.

20 Jul

3 , 3:11 AM
Agilent Technologies, Inc. increases its investment in HALO X-ray Technologies. Increased investment in HALO X-ray Technologies may enhance Agilent's technological offerings and market position.

14 Jul

4 , 8:00 AM
Agilent Technologies received FDA approval for its PD-L1 IHC 28-8 pharmDx assay in esophageal squamous cell carcinoma, gastric, gastroesophageal junction, and esophageal adenocarcinoma. FDA approval expands use of Agilent's PD-L1 test across multiple GI and esophageal cancers, increasing addressable market and revenue for diagnostics segment.

13 Jul

3 , 4:46 PM
Agilent Technologies reported Q1 earnings, triggering analysis of whether investors should buy, sell or hold the stock based on financial results and outlook. Post-earnings analysis can moderately sway short-term investor sentiment and stock trajectory for Agilent.

9 Jul

4 , 1:53 PM
Agilent Technologies expands AI capabilities to strengthen biopharma growth prospects. AI expansion in biopharma represents major strategic move likely to alter company trajectory and investor sentiment.

8 Jul

3 , 8:00 AM
Agilent Technologies expands its Altura portfolio with inert size exclusion and PLRP-S columns for biotherapeutic analysis. Portfolio expansion in biotherapeutics strengthens Agilent's analytical solutions offerings and competitive stance.

1 Jul

4 , 8:00 AM
Agilent Technologies launches AI-driven analysis module for xCELLigence RTCA eSight platform. AI module launch strengthens core cell analysis product line and competitive positioning.

26 Jun

3 www.medtechdive.com, 6:00 AM
Agilent Technologies, Inc. completed its takeover of Biocare Medical. Completed takeover adds Biocare Medical capabilities to Agilent operations.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us